Center of Excellence for Flow Cytometry, Office for Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Asian Pac J Allergy Immunol. 2011 Jun;29(2):181-9.
We have previously shown that monitoring of CD38 expression can be used as a marker for antiretroviral drug efficacy in HIV infected patients. However, the detection of CD38 expression may be affected by the sensitivity of the fluorochrome conjugated reagent.
In this study, we determined the level of CD38 expression using PE and FITC conjugated anti-CD38 monoclonal antibodies in different groups of HIV infected patients.
The frequency and mean fluorescence intensity of CD38 expression using PE and FITC conjugated anti-CD38 monoclonal antibodies were detected by flow cytometry either alone or in combination with HLA-DR. A correlation between CD38 expression and CD4 count, the percentage of CD4 or viral load in antiretroviral drug naive HIV infected patients was performed. The results were compared with those for antiretroviral treated HIV infected patients who responsed to therapy and patients with virological failure.
We found that while both reagents had the ability to detect a high frequency of CD38 expressing cells in untreated patients, only PE conjugated reagent provided correlation with markers for disease progression. More importantly, FITC conjugated reagent cannot monitor the increase in CD38 expression in patients who showed virological failure.
The results from this study suggest that a cautious selection of fluorochrome conjugated reagents and a method for utilizing the data are extremely critical in the use of CD38 expression as a monitoring tool for ART efficacy.
我们之前已经表明，监测 CD38 的表达可以作为 HIV 感染患者抗逆转录病毒药物疗效的标志物。然而，CD38 表达的检测可能会受到荧光染料偶联试剂的灵敏度的影响。
在这项研究中，我们使用 PE 和 FITC 偶联的抗 CD38 单克隆抗体在不同组的 HIV 感染患者中测定 CD38 的表达水平。
通过流式细胞术单独或与 HLA-DR 联合检测 PE 和 FITC 偶联的抗 CD38 单克隆抗体的 CD38 表达频率和平均荧光强度。在未接受抗逆转录病毒药物治疗的 HIV 感染患者中，对 CD38 表达与 CD4 计数、CD4 百分比或病毒载量之间的相关性进行了评估。并将结果与对治疗有反应的抗逆转录病毒治疗的 HIV 感染患者和病毒学失败的患者进行比较。
我们发现，虽然两种试剂都能够检测到未经治疗患者中高频率的 CD38 表达细胞，但只有 PE 偶联试剂与疾病进展的标志物相关。更重要的是，FITC 偶联试剂不能监测病毒学失败患者中 CD38 表达的增加。
这项研究的结果表明，在将 CD38 表达作为抗逆转录病毒治疗效果的监测工具时，对荧光染料偶联试剂的谨慎选择和数据利用方法非常关键。
